Pharmaceuticals company Amneal Biosciences disclosed on Tuesday the approval and availability of its Triamcinolone Acetonide Injectable Suspension, USP in 40 mg/ml dosage strength directly and through wholesalers and distributors.
According to the company, its triamcinolone acetonide will be sold in 1 ml single-dose vials as well as in 5 ml and 10 ml multiple dose vials.
The company added the triamcinolone acetonide injectable suspension is the only AP-rated generic equivalent to KenalogR-40 injection available in the market.
Annually, the US sales of Kenalog-40 injection were USD146m, according to October 2017 IQVIA market data, concluded the company.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream